Published in Obesity and Diabetes Week, October 9th, 2006
Known as BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), this double-blind, randomized, and placebo-controlled trial will include about 100 centers in the United States and is expected to enroll approximately 3,000 overweight and obese patients. The proportion of patients with a 5% or greater weight reduction from baseline at week 52 is the primary endpoint.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week